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Protein  Function  Reference Ena/VASP  Promotes actin filament elongation, anti‐capping, and bundling  (Krause et al., 2003) mDia  Nucleates actin filaments  (Peng et al., 2003) 
Myosin‐X  Mediates intra‐filopodial transport, initiates filopodia by converging actin filaments at the cell edge  (Berg et al., 2001)  IRSp53  Scaffolding protein, deforms membranes to promote protrusion  (Nakagawa et al., 2003) 
Integrins  Mediate cell‐substrate adhesion by binding to extracellular matrix proteins 
(Galbraith et al., 2007; Grabham and Goldberg, 1997; Letourneau and Shattuck, 1989; Partridge and Marcantonio, 2006; Rabinovitz and Mercurio, 1997; Steketee and Tosney, 2002; Wu et al., 1996) 
Cadherins  Mediate cell‐cell adhesion through homotypic interactions  (Vasioukhin et al., 2000; Raich et al., 1999; Wood et al., 2002; Millard and Martin, 2008)  
EGFR  Binds to epidermal growth factor and signals for cell growth, proliferation, and differentiation  (Lidke et al., 2005) 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Figure 4.3.  The FERM domain of myosin­X does not activate αIIbβ3.  CHO cells stably expressing integrin αIIbβ3 were used to test various GFP‐tagged constructs for integrin activation.  Treatment with MnCl2 was used to reveal a maximal level of integrin activation.  The monoclonal antibody PAC‐1, which recognizes the activated form of αIIbβ3, was applied to the cells and quantified using flow cytometry.  Histograms representing the levels of PAC‐1 staining are displayed along with the average PAC‐1 staining for each condition.  Note that GFP‐talin‐FERM, which is known to activate integrins, gives a mean PAC‐1 staining intensity in between the positive (GFP + MnCl2) and negative (GFP) controls, while GFP‐Myo10‐FERM gives a value similar to the negative control. 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Figure 4.4.   Myosin­X does not contain the loop structure necessary to activate 
integrins.  (A) Ribbon and space‐filled models depicting the contacts between the FERM domain of talin (yellow ribbon or grey space‐filled) and the cytoplasmic tail of β3 integrin (red ribbon or red molecular chain).   Reproduced from {{106 Wegener,K.L. 2007;}}.  Note Loop 1‐2 with specific residue L325 of talin‐FERM.  (B) Alignment of lobes F2 and F3 of the talin and Myo10 FERM domains.  (C) Zoomed in alignment highlighting the Loop 1‐2 region of talin‐FERM.  Although the neighboring sections of sequence share high similarity, the Loop 1‐2 is absent from Myo10‐FERM.  Subsequently, the flexible loop with residue L325, which is critical for β3 activation, is not present in Myo10. 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Figure 4.5.  Myosin­X co­transports with integrins in filopodia.  (A) Montage of selected frames from a time lapse movie of a HeLa cell transiently expressing mCherry‐Myo10 and α5‐GFP.  (B) and (C) Kymographs of the filopodia noted by arrowheads in panel (A). (D), (E), and (F) Kymographs of filopodia from a HeLa cell transiently expressing mCherry‐Myo10 and α5‐GFP.  (G) Kymograph of a filopodium from a HeLa cell transiently expressing mCherry‐Myo10 and β3‐GFP.  (H) Kymograph of a filopodium from a HeLa cell transiently expressing mCherry‐Myo10 and β1‐GFP.  Movies 4.1 to 4.4 correspond to the kymographs shown here and are found on the supplementary DVD.
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Figure 4.6.  Myosin­X cotransports with integrins on actin bundles in CAD cells.  (A) Montage of selected frames from a time‐lapse movie of a CAD cell transiently expressing GFP‐Myo10 and labeled with anti‐β1‐conjucated quantum dots.  Note from the phase contrast images that filopodia in CAD cells are often short and contain bundles of actin that extend deeply into the lamella.  Movie 4.5 corresponds to this montage and is found on the supplementary DVD. (B) Kymograph of the region denoted in panel (A). 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CHAPTER 4 MOVIE LEGENDS  
Movie 4.1.  Time‐lapse movie of a HeLa cell transiently expressing mCherry‐Myo10 and α5‐GFP.  This movie corresponds to the montage shown in Figure 4.5.A and the kymographs shown in Figure 4.5.B and C.  Note the faster forward movements of Myo10 and α5 versus the slower rearward movements.  
Movie 4.2.  Time‐lapse movie of a HeLa cell transiently expressing mCherry‐Myo10 and α5‐GFP.  This movie corresponds to the kymographs shown in Figure 4.5.D‐F.   
Movie 4.3.  Time‐lapse movie of a HeLa cell transiently expressing mCherry‐Myo10 and β3‐GFP.  This movie corresponds to the kymograph shown in Figure 4.5.G.   
Movie 4.4.  Time‐lapse movie of a HeLa cell transiently expressing mCherry‐Myo10 and β1‐GFP.  This movie corresponds to the kymograph shown in Figure 4.5.H.   
Movie 4.5.  Time‐lapse movie of a CAD cell transiently expressing GFP‐Myo10 and labeled with anti‐β1‐conjugated Qunatum dots.  This movie corresponds to the montage and kymograph shown in Figure 4.6.  Note the initial slow, rearward movement of the bundle‐associated Quantum dot followed by the fast, forward movement towards the tip of the short filopodia.  Also note the random wiggling of Quantum dots attached to the surface of the cell.  These are presumably bound to integrins on the dorsal surface of the cell that are diffusing in the plasma membrane.  
CHAPTER 5 
MYO19 IS A NOVEL MYOSIN THAT ASSOCIATES WITH MITOCHONDRIA 
 Mitochondria are organelles that have central roles in cell physiology.  One of the first described and most fundamental functions of the mitochondrion is to carry out oxidative phosphorylation to generate ATP from energy‐rich molecules.  As the cell’s “energy powerhouse”, mitochondria are essential for providing ATP for a vast number of cellular functions.  In addition to their critical role in energy production, mitochondria are key players in a wide range of cellular activities such as calcium homeostasis (Spat et al., 2008), apoptosis (Kuwana and Newmeyer, 2003), reactive oxygen species (ROS) production (Wallace and Fan, 2009), development (Van Blerkom, 2009), cell cycle progression and cell signaling (McBride et al., 2006).   As with any component of the cell whose function is fundamental to homeostasis, mutations that arise in these components can lead to disease.  Several diseases have been identified that are caused by defective mitochondrial function.  For example, mutations in mitochondria‐associated proteins lead to skeletal muscle and brain pathologies such as MERRF syndrome (myoclonic epilepsy associated with ragged‐red 
fibers), MELAS syndrome (mitochondrial encephalomyopathy, lactic acidosis, and 
stroke‐like episodes), Charcot‐Marie‐Tooth disease, and Kjer’s disease/autosomal dominant optic atrophy (Wallace and Fan, 2009; Chan, 2006a).  Importantly, aberrant 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mitochondrial function has been implicated other complex conditions such as the degenerative Alzheimer’s, Parkinson’s, and Huntington’s diseases (Celsi et al., 2009), diabetes (Lowell and Shulman, 2005), aging (Balaban et al., 2005), and the progression of cancer (Gogvadze et al., 2008).    Mitochondrial dynamics and localization are central to mitochondria function in both normal and disease states and have been studied in detail.  First, mitochondria fission and fusion are critical to maintaining an effective mitochondrial network.  The cell maintains the overall size and shape of its mitochondria through the opposing processes of fission and fusion and imbalances in these processes lead to mitochondria fragmentation or elongation.  The GTPases Mitofusin1, Mitofusin2, and OPA1 are known to participate in mitochondrial fusion, while dynamin‐related protein 1 (Drp1), Fis1, and Endophilin B1 are known to participate in mitochondrial fission (Chan, 2006b; Liesa et al., 2009).  Mutations in the genes for these proteins can lead to an imbalanced mitochondrial population and cause diseases such as Charcot‐Marie‐Tooth disease or dominant optic atrophy (Chan, 2006a).      Next, the dynamics of mitochondria transport along the cytoskeleton is a critical component of proper mitochondria function.  Mitochondrial movements have been most intensively studied in neurons where research has revealed the transport of mitochondria along the axon (reviewed in (Hollenbeck and Saxton, 2005)).  Several groups have observed anterograde and retrograde transport of mitochondria along the axon and mitrochondria relocation to specific areas within the axon in response to intracellular calcium signals, local ATP needs, axon outgrowth, or other physiological stimuli.  Many of these observed movements were demonstrated to occur along 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microtubules via microtubule‐based motors.  Specifically, the kinesisn‐1 family member KIF5B and the kinesin‐3 family member KIF1B associate with mitochondria and participate in anterograde transport (Nangaku et al., 1994; Tanaka et al., 1998), whereas cytoplasmic dynein has been implicated in retrograde transport (Martin et al., 1999; Waterman‐Storer et al., 1997).  In addition to the microtubule cytoskeleton, the actin cytoskeleton is involved in mitochondria transport.  In studies using drug treatments to depolymerize the microtubule or actin networks, Morris and Hollenbeck found that disrupting the actin network reduced the velocity of both anterograde and retrograde mitochondria transport (Morris and Hollenbeck, 1995).   Moreover, without an actin network, mitochondria spent 3‐fold more time moving retrograde versus anterograde, thus imbalancing overall mitochondria trafficking and resulting in a decreased number of mitochondria that reached the distal axon.  Until recently, no myosin motor was known to interact with mitochondria.  Altmann et al reported that in budding yeast, Myo2 (mammalian Myo5) is involved in transporting mitochondria along actin cables during cell division (Altmann et al., 2008).  This result was exciting, since it was the first account of a myosin motor participating in the transport of mitochondria, but it did not consequently reveal the myosin responsible for actin‐based movements in mammalian cells; Myo5, the mammalian homolog of yeast Myo2, does not associate with mitochondria.  Together these data suggest that a myosin motor may be involved in mitochondria transport in mammalian cells, but to date, no such myosin has been identified.  Here we report the discovery of myosin‐XIX (Myo19), the founding member of a novel class of myosin that associates with mitochondria in mammalian cells.  
 87 
 
MYO19 ENCODES A NOVEL METAZOAN MYOSIN   Previous sequence analysis predicted an uncharacterized myosin gene on human chromosome 17q12 that appeared to represent a novel myosin class (Berg et al., 2001).  Using the database sequence FLJ22865 (myohd1, GI:14286205), we generated PCR primers to clone the full‐length coding region of this putative myosin from human pancreas cDNA.  Sequence analysis of the PCR‐amplified clone revealed a 970aa coding region consisting of a myosin motor domain, a neck region containing three IQ motifs, and a short tail (Figure 5.1).  The Myo19 motor domain shares ~35% sequence identity with the motor domains of human skeletal muscle myosin, Myo5a, and Myo6.  Additionally, the motor contains the conserved GESGAGKT sequence from the P‐loop, DXXGFE sequence from switch‐2 (DVYGFE), and a slightly divergent MEAFGNACTLRNNNSSRFGK in the switch‐1 region (Supplemental Figure 5.1.A, reviewed in (Cope et al., 1996)).  Myo19 has a glutamine at the TEDS position, indicating that it is not regulated by heavy‐chain phosphorylation at this site (Bement and Mooseker, 1995).  The three IQ motifs in the neck region are expected to bind calmodulin or calmodulin‐like light chains (Cheney and Mooseker, 1992).  The 146aa tail domain of Myo19 is basic (pI ~9.2) and is not predicted to form a coiled‐coil (Lupas et al., 1991).  Interestingly, the tail has no obvious sequence homology with other proteins in the databases, except for other Myo19 orthologs (Figure 5.1.B).  Clear orthologs of human Myo19 are present in multiple vertebrate species including mouse (GI:56206893), chicken (GI: 118100337), Xenopus laevis (GI:62185680), and zebrafish (GI:189519181).  Furthermore, at the amino acid level, human Myo19 (970aa) exhibits 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82% identity to mouse Myo19 (963aa) and 56% identity to Xenopus laevis Myo19 (971aa).  Although Myo19 arose early in metazoan evolution, it appears to have been lost from lineages leading to Drosophila and C. elegans (Odronitz and Kollmar, 2007).    
MYO19 IS EXPRESSED IN MULTIPLE TISSUES AND CELL LINES   To determine the tissue expression pattern of Myo19, we probed a Northern blot using a sequence from the 3’ non‐coding region.  A band of approximately 4.2kb was detected in multiple tissues (Figure 5.2.A).  Although the sample from human brain did not react strongly with this probe, analysis of ESTs and the Allen Brain Atlas (http://www.brain‐map.org) indicate that Myo19 is broadly expressed in vertebrate tumors, cells, and tissues, including brain.  Antibodies raised against the human Myo19 peptide AKELDGVEEKHFS (aa 829‐841) detected a protein of the expected size of ~109kD in western blots of human and other primate cell lines (Figure 5.2.B).  We also detected Myo19 in mouse cell lines (B16‐F1 and CAD) using this antibody, but the signal was weaker, likely due to sequence differences in the antibody target (SKELDGMEEKPMP in mouse).   To study mouse Myo19 in addition to human, we raised 2 antibodies against bacterially expressed and purified mouse Myo19 tail sequence.  The anti‐mMyo19 antibody #42 (Ab42) recognized a protein of the expected size of ~109kD in mouse cells (B16 and CAD), but not in human cells (A549) (Figure 5.2.C).  When mouse cells were transfected with either full‐length hMyo19 or the tail of hMyo19, Ab42 could only detect endogenous mMyo19, whereas anti‐mMyo19 antibody #43 (Ab43) could detect either endogenous mouse or exogenous human Myo19 (Figure 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5.2.D).  Together, our antibodies detected a protein of predicted size in several cell types from different species and tissues.  
MYO19 LOCALIZES TO MITOCHONDRIA   To reveal the cellular localization of Myo19, we immunostained multiple cell lines (B16, NIH3T3, A549, HeLa, and COS‐7) with anti‐Myo19 antibodies.  Colocalization with mitochondrial markers revealed clear and striking localization of endogenous Myo19 to mitochondria (Figure 5.3).  Next, we performed differential centrifugation on NIH3T3 homogenates to determine if Myo19 separated into fractions along with a known mitochondrial marker.  With increasing centrifugal force, endogenous Myo19 indeed followed the mitochondria marker porin from supernatant to pellet (Figure 5.4).    To determine the region of Myo19 required for mitochondrial localization, we generated a series of GFP‐constructs containing different regions of the human Myo19 protein.  When expressed in A549 (Figure 5.5.A) or B16 cells (not shown), full‐length GFP‐Myo19 and a “tail” construct containing amino acids 801‐970 both clearly localized to mitochondria.  However, a construct containing the motor domain and IQ motifs (amino acids 1‐828) did not localize to mitochondria and exhibited punctate cytoplasmic staining (Figure 5.5A).  To test if Myo19 is anchored to the mitochondrial outer membrane via insertion of a c‐terminal transmembrane helix (Borgese et al., 2003), we added GFP to the c‐terminus of our constructs (Horie et al., 2002).  Expression of either a Myo19 tail or a full‐length Myo19 construct GFP‐tagged at the c‐terminus resulted in mitochondrial localization.  Taken together, these data indicate 
 90 
that the tail domain of Myo19 is necessary and sufficient for mitochondrial localization via a mechanism that is likely not a c‐terminal transmembrane helix (Figure 5.5.B).    
EXPRESSING GFP­MYO19 ALTERS MITOCHONDRIAL DYNAMICS   Due to its striking endogenous localization to mitochondria, we next wondered if Myo19 functions in actin‐based mitochondrial motility.  To test Myo19’s role in mitochondrial dynamics, we used time‐lapse imaging to monitor the movements of mitochondria in GFP‐Myo19 transfected cells versus Mito Tracker labeled or fluorescently‐tagged mitochondrial targeting sequence transfected control cells.  In control cells, the vast majority of mitochondria remained largely in place with only small "jostling" movements (Movie 5.1).  The rare mitochondria that underwent long‐range, end‐on movement in these cells traveled with a velocity of 102±7nm/s (n=27 mitochondria, 6 cells).   Expressing GFP‐Myo19, however, led to a dramatic increase in mitochondrial motility (Movie 5.2 and Figure 5.6).  In approximately 40% of the cells expressing GFP‐Myo19, the majority of mitochondria moved continuously for many microns with one end of the mitochondrion leading.  The leading end was often wider than the trailing end, resulting in a tadpole‐like appearance (Figure 5.6.B, Movie 5.3).  Unlike microtubule‐dependent movements, these mitochondria did not follow linear tracks and their movements were not obviously directed towards or away from the cell center (Figure 5.6.A).  The mitochondria in GFP‐Myo19 cells that were moving continuously had an average velocity of 73±3nm/s (n=125 mitochondria, 8 cells).     To quantify the increase in mitochondrial motility induced by GFP‐Myo19, we measured the average velocities of randomly selected mitochondria in control A549 
 91 
cells and A549 cells transfected with GFP‐Myo19.  The velocities of control mitochondria formed a broad peak centered at relatively low values, while the velocity distribution for GFP‐Myo19 mitochondria was shifted to the right and had an additional small peak in the 50‐75 nm/s range (Figure 5.6.C).  The average velocity of randomly selected mitochondria in the control cells was 16±1nm/s (n=122 mitochondria, 12 cells).  Expressing GFP‐Myo19 resulted in an average velocity of 28±2nm/s (n=163, 8 cells; p<4x10‐8), a 75% increase over control cells.  Since these measurements included mitochondria from all GFP‐Myo19 cells, including those that exhibited little movement, the average velocity from only the ~40% of A549 cells that exhibited overall increased mitochondrial motility would be even greater.   As an additional measure of mitochondrial dynamics, we also determined a "Displacement Index" (D.I.) by dividing the area over which mitochondrial network moved in a 3:20 (min:sec) time‐lapse by the area occupied by mitochondria in the first frame of the recording (Figure 5.7).  If the mitochondrial network remained perfectly stationary, then D.I.=1.  Control A549 cells had a D.I. of 1.2±0.1 (n=10, p<5x10‐5, Figure 5.7.A), whereas the D.I. in GFP‐Myo19 cells increased by 75% to 2.1±0.7 (n=28), again demonstrating that expression of GFP‐Myo19 dramatically increases mitochondrial motility.    
GFP­MYO19 INDUCED MITOCHONDRIAL MOTILITY IS LIKELY DUE TO MYO19 
MOTOR ACTIVITY We hypothesize that the movements of mitochondria we observed are powered by Myo19 moving on randomly organized actin filaments.  To test if these movements 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are in fact actin‐based, live cells expressing full‐length GFP‐Myo19 were treated with 15µM nocodazole to disrupt microtubules or 500nM latrunculin B to disrupt F‐actin.  This dose of nocodazole was sufficient to disrupt the distribution of the endoplasmic reticulum within 5 minutes (data not shown).  Mitochondrial movements induced by GFP‐Myo19 were insensitive to nocodazole treatments lasting as long as least twenty minutes (Figure 5.8, Movie 5.4).  These mitochondria continued to display movement over many microns and the tadpole shape remained.  However, upon addition of latrunculin B to nocodazole‐treated cells, the end‐on, directed movements ceased (Figure 5.8, Movie 5.4).  In addition, the mitochondria lost their asymmetric shape within 2 minutes of latrunculin B treatment (Figure 5.8.C).  Treatment of cells with latrunculin B without nocodazole pretreatment also resulted in a prompt cessation of end‐on mitochondrial movement and a rapid loss of the asymmetric shape, demonstrating that both the motility and altered shape are dependent on the presence of F‐actin (Movie 5.5).    
siRNA OLIGOS DIRECTED AGAINST MYO19 EFFECTIVELY KNOCK­DOWN MYO19 
PROTEIN   The discoveries that Myo19 localizes to mitochondria and that over‐expression of Myo19 led to a dramatic increase in mitochondrial dynamics were quite intriguing and raised an obvious next question: what is the function of endogenous Myo19?  To address this question, we sought to examine the loss of function phenotype in Myo19 knock‐down cells.  Numerous previous attempts to perform such experiments in human cells using siRNA and morpholino strategies proved unsuccessful.  This was in large 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part because the chicken anti‐human antibody used to screen for knock‐down gave a low signal and high background in Western blotting.  Therefore, I began characterizing the rabbit anti‐mouse Myo19 antibodies (as shown in figures 5.2, 5.3, and 5.4).  With the reproducible success of these antibodies, I decided to test for the Myo19 loss of function phenotype in mouse cells.  To achieve this aim, I designed five siRNAs against mouse Myo19 (Figure 5.9.A) and used B16 cells to test several concentrations and lengths of exposure for each siRNA (Figure 5.9.B).  Within the conditions I tested, all of the siRNA sequences knocked‐down Myo19 to some extent, although sequence #2 appeared most effective.  Overall, I was able to achieve maximum knock‐down of Myo19 protein in the range of 50‐90%, as detected by Western blot.  These results were exciting, as now we have a strategy to examine the effects of endogenous Myo19 knock‐down.   Next, I used my siRNA protocol to perform some preliminary loss of function  studies.  I first was interested to know if Myo19 knock‐down affected mitochondrial shape, size, or distribution.  Changes in mitochondria shape and/or size would suggest that Myo19 may participate in mitochondria fusion or fission, as knock‐down of proteins that participate in mitochondria fusion and fission result in fragmented or elongated mitochondria populations, respectively (Chen and Chan, 2004; Detmer and Chan, 2007).  Alternatively, the increase in mitochondrial dynamics following Myo19 over‐expression suggests that Myo19 may play a role in mitochondria positioning; therefore Myo19 knock‐down could result in an abnormal distribution of mitochondria.  To begin testing these possible functions for Myo19, I treated B16 cells with non‐specific or Myo19‐specific siRNA for four days, labeled mitochondria with Mitotracker, 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fixed, and imaged the cells. In these preliminary experiments, I did not see an obvious qualitative defect in mitochondrial shape, size, or distribution (not shown).  Although these initial experiments using my Myo19 knock‐down strategy did not reveal an obvious phenotype, we now have the tools and methods necessary to uncover the endogenous role of Myo19 by testing its function in a number of different assays, as discussed below.   
MYO19 IS A NOVEL MITOCHONDRIA­ASSOCIATED MYOSIN THAT IS LIKELY TO 
FUNCTION IN ACTIN­BASED MITOCHONDRIA DYNAMICS   Taken together, our data strongly suggest that Myo19 is a broadly expressed mitochondrial myosin involved in actin‐mediated mitochondria movement and positioning.  Endogenous Myo19 localizes to mitochondria, as revealed by immuno‐staining and differential centrifugation, and truncation analyses indicate that this localization is via Myo19’s tail.  Expression of full‐length GFP‐Myo19 protein induces a dramatic increase in mitochondrial motility in A549 and B16 cells and we observed similar increases in mitochondrial motility in COS‐7 cells (data not shown).  As predicted for myosin‐driven movements, these movements are indeed actin based, as GFP‐Myo19‐induced movements cease upon destabilization of the actin network.  Since the striking increase in mitochondrial motility was not observed in 100% of the cells expressing GFP‐Myo19, it is likely that additional factors regulate Myo19 function and/or mitochondrial movement.  Whether those conditions are related to the amount of Myo19 on the mitochondrial surface or activation state of Myo19 motor has yet to be determined. 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 Although our over‐expression data revealed an obvious gain of function for Myo19, our initial knock‐down results were not clear.  Preliminary analysis of Myo19 knock‐down cells did not display a defect in mitochondria shape, size, or distribution.  Investigating these mitochondrial attributes was quite difficult, as mitochondria are known to be heterogeneous and pleiomorphic (Collins et al., 2002; Rube and van der Bliek, 2004), but qualitative analysis did not reveal the gross defects seen in knock‐down of fusion or fission proteins.  Additionally, we did not observe obvious changes in the distribution of mitochondria when Myo19 was knocked‐down in B16 cells; however, mitochondria distribution in wild‐type B16 cells is heterogeneous.  It is possible that B16 cells are not the ideal model to test for changes in mitochondria position following knock‐down of Myo19.  A cell type such as neurons or polarized epithelial cells, which require spatially disparate energy needs, may normally have a less heterogeneous mitochondria distribution.  Knock‐down of Myo19 in such a cell type could reveal a role for Myo19 in mitochondrial positioning and distribution.   An alternative possibility for a Myo19 null phenotype, as implicated by the gain of function phenotype of increased mitochondrial dynamics, is that knock‐down of Myo19 will result in decreased mitochondrial motility.  Unfortunately, the normally low level of mitochondrial dynamics in B16 cells makes it difficult to assess how knock‐down of Myo19 effects mitochondrial movements in our current system.  Just as described above for mitochondria positioning and distribution, it may be important to find a cell type that normally exhibits a high degree of mitochondrial dynamics.  In addition, it may be possible to identify drugs or cellular conditions that induce an increase in mitochondria movements.  For example, decreasing calcium levels with 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treatment with either the calcium chelator BAPTA‐AM or activation of protein kinase C with phorbol myristate acetate can increase mitochondrial motility (Saotome et al., 2008; Wang and Schwarz, 2009; Nekrasova et al., June 2007).  Treatment of control versus Myo19 knock‐down cells with these drugs may reveal a defect in mitochondrial dynamics that is not otherwise apparent in untreated cells.   While it is possible that we could see dramatic changes in mitochondrial dynamics following Myo19 knock‐down, perhaps Myo19 plays a more subtle role in mitochondria movements.  In wild‐type B16, A549, and HeLa cells, we routinely observe a constant “jostling” movement of the mitochondria.  These movements may represent a form of perpetual interaction with the surrounding actin cytoskeleton powered by Myo19.  Furthermore, transient Myo19‐mediated interactions with the actin cytoskeleton may play an important role in conjunction with microtubules‐based mitochondrial movements.  As mitochondria move across long distances via microtubule‐based motors, pauses along the journey could be the result of Myo19 interacting with the surrounding actin as it passes by.  These more subtle roles for Myo19 could be important not so much for transporting mitochondria, but for anchoring them in specific cellular locations. Lastly, it is important to note that although we suggest several possible roles for Myo19 in mitochondria function, defects in these processes may not be apparent in knock‐down cells with only a 50% reduction in Myo19 protein.  If very low amounts of Myo19 are sufficient to sustain a functioning mitochondria system, we may need to reduce the levels of Myo19 protein by 90% or more to reveal a Myo19‐null phenotype.  To address this concern, we are currently creating a Myo19‐shRNA construct for use 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with the pLL lentivirus system (Rubinson et al., 2003).  With this system, the shRNA directed against Myo19 will be stably inserted into the genome, allowing for a longer period and higher percentage of Myo19 knock‐down.  Under these conditions, it will be more feasible to determine in which of the duties described above Myo19 is participating.   The localization and dynamics of mitochondria are critical to mitochondrial function and disruption of these processes leads to human disease (Zuchner et al., 2004; Delettre et al., 2002).  Mitochondrial localization and dynamics have been shown to involve both microtubules and actin (Nangaku et al., 1994; Tanaka et al., 1998; Altmann et al., 2008; Boldogh et al., 2001; Minin et al., 2006).  However, the mechanism of actin‐based mitochondrial movements in vertebrates remains unclear (Hollenbeck and Saxton, 2005).  Here we report the discovery of a novel mitochondria‐associated myosin, Myo19.  Myo19 is the founding member of a novel class of myosins and is the last uncharacterized myosin in humans.  We show that Myo19 exhibits striking localization to mitochondria and that this localization is mediated through its tail.  Additionally, we demonstrate that over‐expression of Myo19 results in a remarkable gain of function phenotype, in which mitochondria become more motile and dynamic.  Finally, we developed an siRNA strategy to knock‐down Myo19 in mouse cells, which can be used in the future to uncover the endogenous role of Myo19.  Our discovery of a novel class of myosin that localizes to mitochondria provides a possible molecular mechanism for actin‐based mitochondrial movements. 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EXPERIMENTAL PROCEDURES 
PCR cloning.  The full‐length human Myo19 construct was cloned from a QUICK‐Clone pancreas cDNA mix (Clontech) using the primers listed in Quintero et al, 2009.  The 3.7 kb band (as visualized by agarose gel electrophoresis) was then extracted and cloned into the pCR 2.1‐TOPO cloning vector (Invitrogen) as per the manufacturer’s protocol.  After the verification of the fragment’s sequence by direct sequencing, this clone was used to generate all subsequent GFP constructs of Myo19 by adding restriction sites that would allow insertion into the correct pEGFP expression vector (Clontech).  All clones were verified by sequencing. 
Northern blotting.  A 433 bp oligonulceotide probe to the 3’‐untranslated region of the predicted human Myo19 mRNA was generated by PCR (forward primer 5’‐TGCCTCAGGGATCGATAAAG‐3’ and reverse primer 5’‐CATGACTGCTGCTGAGTTTGA‐3’) from a previously generated PCR clone of the Myo19 mRNA. The probe was end‐labeled with 32P using Ready To Go DNA labeling beads (Amersham), according to the manufacturer’s directions, and unincorporated counts were removed by ProbeQuant G‐50 Micro Column (Pharmacia Biotech).  The probe was added to the hybridization solution to a final concentration of 2 x 106cpm/mL, and a human multiple tissue blot (BD Biosciences) was hybridized under stringent conditions and washed according to the manufacturer’s directions.  The blot was then exposed using a phosphorimager. 
Antibody production.  For biochemical studies and immunolocalization, antibodies were raised in chickens against a synthetic peptide sequence consisting of amino acids 829‐841 of human Myo19 (AKELDGVEEKHFS).  Two chickens were immunized and the antibodies specific to the peptide were isolated by affinity 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chromatography using the immobilized peptide (Aves Labs).  Additional antibodies were raised in rabbits against a bacterially‐expressed and purified His‐tagged mouse Myo19 tail sequence (Qiagen PQE vector system).  Two rabbits were immunized and the antibodies specific to the Myo19 tail sequence were isolated by affinity chromatography using the immobilized protein. 
Cell culture.  HeLa carcinoma cells and COS‐7 kidney epithelial cells were obtained from the Lineberger Comprehensive Cancer Center, UNC‐Chapel Hill.  A549 pulmonary epithelial cells and B16F1melanoma cells were obtained from Dr. Jo Rae Wright (Duke University Medical Center) and Dr. Gary Borisy (Northwestern University Medical School), respectively.  HeLa cells were maintained in MEM medium supplemented with 10% fetal bovine serum and 100U penicillin‐streptomycin.  A549 cells were maintained in F12K medium supplemented with 10% fetal bovine serum and 100U penicillin‐streptomycin.  COS‐7 and B16F1 cells were maintained in DMEM medium supplemented with 10% fetal bovine serum and 100U penicillin‐streptomycin.  Cells were passaged using 0.25% trypsin‐EDTA (Invitrogen) and plated onto the required substrate (cell culture flasks or glass slides) depending upon the requirements for the experiment. 
Immunoblotting.  For western blots to determine the presence of Myo19 protein, cells from 100mm cell culture dishes that were 80% confluent were scraped directly into 1mL of lysis buffer (10mM HEPES, 2mM EDTA, 10% sucrose, Sigma protease inhibitor cocktail, pH7.4), mixed with 5x SDS‐PAGE sample buffer, and boiled at 95°C for 5 minutes prior to loading on a 4‐20% Tris‐glycine SDS‐PAGE gel.  Samples were then transferred to nitrocellulose at 150 V‐hr in transfer buffer (25 mM Tris, 192 mM 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glycine, 20% methanol, 0.02% SDS). Affinity purified antibodies were used at 0.3‐1 µg/ml with 1:10,000 donkey anti‐chicken or donkey anti‐rabbit (Jackson) secondary antibody conjugated to horseradish peroxidase.  Immunoblots were developed using SuperSignal West Pico chemiluminescent substrate (Pierce). 
Immunostaining.  HeLa, A549, or COS7 cells were plated onto acid‐washed coverslips or B16 cells were plated onto laminin‐coated coverslips in a 6‐well cell culture dish in their appropriate media overnight.  For cells labeled with Mitotracker to stain mitochondria, cells were incubated with 1‐5nM Mitotracker CMX‐Ros for 10 minutes, and then washed three times for 10 minutes with the appropriate cell culture medium.  The cells were fixed with 3.7% paraformaldehyde in PBS for 7 minutes, permeabilized with 0.5% Triton X‐100 for 2 minutes, and blocked in 5% goat serum in PBS for 1 hour.  Coverslips were incubated with specific antibodies at 0.5‐5 µg/ml for 1 hour, rinsed three times for 15 minutes in PBS, incubated with Alexa488‐ and/or Alexa568‐conjugated secondary antibodies (Molecular Probes) at 1 µg/ml for 60‐90 minutes, and rinsed three times in PBS for 10 minutes.  Coverslips were mounted using 90% glycerol containing 0.5% N‐propyl gallate or GelMount (BioMedia)and examined using a Nikon fluorescence microscope with a 60x/1.4NA phase objective.  Images were obtained using an Orca ER cooled CCD digital camera (Hamamatsu) or a Coolsnap ES cooled CCD digital camera (Photometrics) and Metamorph software (Universal Imaging). 
Live cell imaging of GFP­Myo19 constructs.  HeLa, A549, or COS7 cells were plated onto acid‐washed coverslips in a 6‐well cell culture dish in their appropriate media overnight.  The cells were then transfected with the appropriate GFP‐Myo19 construct, 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either alone or in combination with pDsRed2‐Mito (Clontech) using Polyfect transfection reagent (Qiagen) according to the manufacturer’s protocol.  For B16 cells, cells were transfected overnight, replated onto laminin‐coated coverslips, then imaged the following day.  The coverslips were transferred to imaging chambers containing Imaging Medium (Optimem medium without phenol red supplemented with 5% fetal bovine serum and 100U penicillin‐streptomycin).  For drug treatments, coverslips were mounted in perfusion chambers and the cells were treated with Imaging Medium supplemented 15µM nocodazole, or Imaging Medium supplemented with 500nM latrunculin B.  Time‐lapse images were collected using a Nikon fluorescence microscope with a 60x/1.4NA phase objective.  Images were obtained using an Orca ER cooled CCD digital camera (Hamamatsu) or a Coolsnap ES cooled CCD digital camera (Photometrics) and Metamorph software (Universal Imaging).  During imaging, the cells were maintained at approximately 35°C. 
siRNA.  Target sequences against mouse Myo19 were identified used the siDESIGN Center by Dharmacon.  Non‐specific, siGLO, and Myo19‐specific oligos were ordered from Dharmacon.  B16 cells at 30‐50% confluency were transfected with siRNA oliogs using Lipofectamine 2000 (Invitrogen) according to the manufacturers instructions and following previously reported conditions (Dalby et al., 2004).  Twenty‐four hours after transfection, those cells transfected with siGLO were imaged to determine transfection efficiency.  For experiments in which siRNA‐treated cells would be imaged, cells were replated on coverslips three days after transfection.  Imaging assays and Western blots were performed four or five days after siRNA transfection. 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Data analysis and software used.  Pair‐wise sequence alignments were performed using BLAST (http://blast.ncbi.nlm.nih.gov/bl2seq/) (Tatusova and Madden, 1999).  Sequence alignment was accomplished using ClustalW2 (http://www.ebi.ac.uk/clustalw/) (Larkin et al., 2007).  Mitochondrial velocities were calculated by manually tracking individual mitochondria (moving with a leading end) frame‐by‐frame and calculating average velocity by dividing distance moved by elapsed time.  In the experiments where mitochondria were selected at random, mitochondria to track were selected in the first frame of the time‐lapse, prior to viewing the movie.  Mitochondria that could not be tracked for the entire movie were not included.  In the experiments where the velocities of moving mitochondria were measured, moving mitochondria were identified by viewing the time‐lapse and choosing individual mitochondria that were moving end‐on for at least 5 frames (25 seconds of elapsed time.  Displacement Index (D.I.) was calculated by dividing the cellular area where mitochondria had been present during a 3:20 time‐lapse (as calculated by maximum projection) by the cellular area that contained mitochondria in the first image of the series.  Run length was defined as the distance traveled by a mitochondrion before an apparent pause of two or more frames.  Data were compared using Minitab 12 software by Student's t‐test for unpaired samples or analysis of variance and a Tukey test when appropriate.  Data are expressed as mean ± standard error of the mean.  All images were prepared for publication using Metamorph, Photoshop, or a combination of both software packages. 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Portions of this chapter were reprinted from Current Biology, Volume 19, Issue 23, Omar A. Quintero, Melinda M. DiVito, et. al, “Human Myo19 is a Novel Myosin that Associates with Mitochondria”, pages 2008‐2013, Copyright 2009 Elsevier, with kind permission from Elsevier.
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Figure 5.1.  Myo19 is myosin motor protein with a novel tail domain.  (A) Sequence analysis of Myo19 shows that it contains highly conserved sequences present in myosin motors (underlined) and the IQ motifs present in myosin lever arms.  It is important to note that database entry FLJ22865 corresponds to a 770aa Myo19 sequence lacking 4 sequential exons from the core motor domain and is thus likely to represent either an aberrant cDNA or a splice form with a non‐functional motor.  The 200aa region of the motor domain missing from hypothetical protein FLJ22865 is represented in blue italics.  (B) Although the tail domain of Myo19 does not contain obvious homology to other proteins or domains, sequence alignment of the Myo19 tail domain indicates regions of conservation exist.  Mouse GI:81862507, cow GI:194675806, opossum GI:75750490, chicken GI:118100337, X. laevis GI:62185680, zebrafish GI:189519181.  
(C) Human Myo19 is predicted to consist of a motor domain, neck region with three IQ motifs, and a short tail domain. 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Figure 5.2.  Myo19 is expressed in multiple tissues and cell lines.  (A) A 4.2kb messenger RNA encoding for the Myo19 protein was detected by Northern blot analysis in multiple human tissues at varying levels.   In skeletal muscle, a larger mRNA also appeared to react with the probe.  Although the brain sample in this blot did not show strong reactivity, EST databases do indicate that Myo19 is expressed in brain.  Ladder indicates sizes of molecular weight markers in kilobases (Kb).  (B) Using an antibody raised against a peptide from the tail sequence of human Myo19, a protein of approximately 109kD was detected by western blot.  This antibody cross‐reacted poorly with rodent cell lines (B16 and CAD), but was able to detect Myo19 in human (HeLa and A549) and monkey cell lines (COS‐7).  Ladder indicates sizes of molecular weight markers in kiloDaltons (KDa).  (C) Using an antibody raised against bacterially expressed and purified tail of mouse Myo19, a protein of approximately 109kD was detected by western blot.  This antibody (Ab #42) detected Myo19 in mouse cell lines (B16 and CAD), but did not detect human Myo19 (A549).  Additionally, Ab #42 reacted non‐specficially with a band of approximately 45 KDa in several cell lines.  (D) Two antibodies against mouse Myo19 (Ab #42 and Ab #43) have different cross‐reactivity.  In B16 cells transfected with human Myo19 constructs, Ab #42 only detects endogenous mouse Myo19, whereas Ab #43 can detect either mouse or human Myo19.  Although Ab #43 can detect both mouse and human Myo19, its overall reactivity is weaker than Ab #42. 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Figure 5.3.  Myo19 localizes to mitochondria.  Antibody #42 against mouse Myo19 (green) strongly colocalizes with anti‐OxPhos complex IV subunit I stained mitochondria (red) in B16 cells.  Nuclei are revealed with DAPI (blue).  Chicken anti‐human Myo19 antibody also labels mitochondria in HeLa and COS‐7 cells (not shown). 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Figure 5.4.  Myo19 co­sediments with mitochondria.  NIH3T3 cells were homogenized and subjected to differential centrifugation.  Samples of the supernatant and pellet from each centrifugation step were separated by SDS‐PAGE and Western blotted.  The presence of mitochondria in was detected using antibodies against the mitochondrial membrane protein, porin.  Myo19 was detected using antibody #42.  As revealed by anti‐porin staining, a large portion of the mitochondria pellet out at 600g, indicating that the homogenate contained many cells still intact.  The rest mitochondria released by homogenization pellet at 10,000g.  Importantly, the Myo19 staining closely mirrors the porin staining, with a large portion of Myo19 in the 600g pellet and the remainder in the 10,000g pellet.  Little to no porin or Myo19 protein is detectable in the 150,000g supernatant or pellet.  This data suggests that Myo19 is found in cellular fractions containing mitochondria. 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Figure 5.5.  GFP­Myo19 localizes to mitochondria through its tail domain. (A) Both full length GFP‐Myo19 and a GFP‐Myo19‐tail construct (green) colocalize with Mitotracker‐labeled mitochondria (red) in HeLa (shown), A549, COS‐7, and B16 cells.  Constructs consisting of the motor domain and IQ motifs do not localize to mitochondria.  (B) Amino acids 824‐970 are necessary and sufficient for mitochondrial localization, as GFP constructs consisting of only this sequence of amino acids localize to mitochondria.  GFP is represented by a green oval in the domain diagrams of the constructs in panels (A) and (B).  Scale bars in (A) equal 10 µm. 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Figure 5.6.  Expressing GFP­Myo19 increases mitochondrial motility.  (A) Mitochondria in control A549 cells expressing pDsRed2‐Mito showed little movement.  Expression of GFP‐Myo19 led to a vast increase in the number of mitochondria that moved and the lengths of those movements.  These movements were often non‐linear and did not necessarily correspond to movements towards or away from the nucleus.  Arrows in the top panels represent the initial direction of movement for the indicated mitochondria and the paths taken by those mitochondria during a 4‐minute recording are depicted in the bottom panel.  (B) In addition to inducing motility of mitochondria in A549 cells, expression of full‐length GFP‐Myo19 often led to mitochondria with an obvious taper, where the trailing end was narrower than the leading end, as can be seen by phase contrast imaging or fluorescence imaging.  Tapered mitochondria were rarely 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observed in cells not expressing GFP‐Myo19.  Arrow indicates the direction of movement.  (C) A histogram of velocities of randomly selected mitochondria shows that expression of full length GFP‐Myo19 led to a 75% increase in mitochondrial velocity (*p<4x10‐8).  For pDsRed2‐Mito (control) cells, n=122 mitochondria (12 cells).  For GFP‐Myo19 cells, n=163 mitochondria (8 cells).  Velocities in legend are mean±SEM. 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Figure 5.7.  Expression of Myo19 increases mitochondrial dynamics.  Displacement Index (D.I.) for a 3:20 time‐lapse was calculated by dividing the cellular area where mitochondria had been present during the time‐lapse (as calculated by maximum projection, blue) by the cellular area that contained mitochondria in the first image of the series (red) for (A) pDsRed2‐Mito expressing (control) A549 cells and (B) GFP‐Myo19 expressing A549 cells.  Expression of GFP‐Myo19 led to a dramatic increase in mitochondrial dynamics (C), as indicated by the 75% increase in D.I. compared to control cells (*p<5x10‐5, n = 28 cells for GFP‐Myo19, n = 10 cells for pDsRed2‐Mito).  Data are mean D.I. ±SEM. 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Figure 5.8.  GFP­Myo19 induced movements in A549 cells are actin­depedent.  (A) As can be seen in Movie 5.4, microtubule disruption with 15µM nocodazole failed to inhibit mitochondrial movements or shape change in GFP‐Myo19 expressing A549 cells (drug added at 1minute, 40 seconds).  Arrows in the top panels represent the initial direction of movement and the corresponding tracks over the next four minutes are shown in the bottom panels.  (B) Disruption of actin with the addition of 500nM latrunculin B halted mitochondrial movements (drug added at 26:19).  (C) Latrunculin B also disrupted the tapered mitochondrial shape within two minutes of addition, as visualized by phase contrast microscopy.  
 115 
  
Figure 5.9.  siRNA sequences directed against mouse Myo19 knock­down 
endogenous protein.  (A) Five siRNAs were designed against mouse Myo19 and named siRNA #1‐5.  The nucleotide targets of each siRNA are listed along with the location of each target on the Myo19 protein bar diagram.  (B) B16 cells transfected with fluorescently‐labeled control siRNA oligos (siGLO) are positive for fluorescence one day after transfection.  Visualizing presence of siGLO revealed a >90% transfection efficiency of siRNA oligos.  Western blot analysis of B16 cells treated with non‐specific (‐C or siGLO) or Myo19‐specific siRNA reveals knock‐down of Myo19 protein levels.  siRNA dose (nM) and length of exposure (days) were varied to determine an optimal siRNA treatment.  Under these conditions, siRNA #2 appeared most effective versus the other siRNA sequences.  Protein knock‐down ranged from approximately 50‐90%. 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CHAPTER 5 MOVIE LEGENDS 
 
Movie 5.1.  Mitochondria in B16 cells are mostly stationary.  Live‐cell imaging of a B16 cell labeled with Mito Tracker revealed that although mitochondria exhibited small "jostling" movements, most did not undergo long‐range movements.  Images were captured once every 5 seconds.  Timestamp represents min:sec.  
Movie 5.2.  Expressing GFP‐Myo19 results in a dramatic increase in mitochondrial motility.  B16 cells transiently transfected with GFP‐Myo19 were imaged via time‐lapse fluorescence microscopy.  Expression of GFP‐Myo19 caused majority of the mitochondria in the cell to become motile.  These mitochondria moved with a leading end, but not in straight lines.  Images were captured once every 5 seconds.  Timestamp represents min:sec.  
Movie 5.3.  Expressing GFP‐Myo19 often results in mitochondria with an asymmetric shape.  B16 cells transiently transfected with GFP‐Myo19 were imaged via time‐lapse microscopy.  Expression of GFP‐Myo19 caused majority of the mitochondria in the cell to become motile.  Moving mitochondria often displayed a characteristic “tadpole” shape where the leading end of the organelle was wider than the trailing end and brightly labeled with GFP‐Myo19.   The distorted shape can be seen in both the fluorescence (left) and phase contrast (right) images.  Images were captured once every 5 seconds.  Timestamp represents min:sec.  
Movie 5.4.  GFP‐Myo19‐induced mitochondrial movements are not microtubule‐dependent, but are actin‐dependent.  A549 cells were transiently transfected with GFP‐Myo19 and imaged via time‐lapse fluorescence microscopy.  Cells expressing full‐length GFP‐Myo19 were treated with cytoskeleton destabilizing drugs to identify which filaments are involved in Myo19‐mediated mitochondrial movements.  Media containing 15µM nocodazole was perfused into the imaging chamber at 1:40 (min:sec).  The mitochondria maintained their tadpole shape and continued to move.  Perfusion of media containing 500nM latrunculin B at 26:19 resulted in a cessation of the mitochondrial movements and a loss of the asymmetric mitochondrial shape.  Prior to nocodazole treatment, the average velocity of moving mitochondria in this cell was 120±12nm/s (n=13).  Following nocodazole treatment, the average velocity of moving mitochondria increased slightly to 148±7nm/s (n=22).  Following addition of LatB, end‐on mitochondrial movements ceased.  As can be seen in the phase images, LatB treatment triggered some blebbing but the treated cell remained spread.  Images were captured once every 5 seconds.  Scale bar equals 10µm.  Timestamp represents min:sec.  
Movie 5.5.  GFP‐Myo19 induced mitochondrial movements are inhibited by latrunculin B treatment, even if microtubules are intact.  A549 were transiently transfected with GFP‐Myo19 and imaged via time‐lapse fluorescence microscopy.  Cells expressing full‐length GFP‐Myo19 were treated with media containing 500nM latrunculin B at 7:21 (min:sec).  This perfusion resulted in a cessation of the mitochondrial movements.  Prior to LatB treatment, the average velocity of moving mitochondria in this cell was 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91±10nm/s (n=6).  Following addition of LatB, end‐on mitochondrial movements ceased.  Images were captured once every 10 seconds.  Scale bar equals 10µm.  Timestamp represents min:sec.  
CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS  
MYOSIN­X   Myo10 is a MyTH4‐FERM myosin that localizes to and travels within filopodia, is a master regulator of filopodia formation, and can bind to proteins found at the tips of filopodia (reviewed in Chapter 2).  Specifically, Myo10 can bind to integrins, but the consequence of this interactions in largely unknown.  Here, I provide evidence that suggests that Myo10 co‐transports integrins to the tips of filopodia.  Moreover, this interaction appears to be important during cell spreading and adhesion, when integrin‐rich filopodia are known to mediate initial contacts between the cell and its substrate (Partridge and Marcantonio, 2006).  However, the interaction between the FERM domain of Myo10 and β‐integrins does not appear to increase integrin activation, unlike the FERM domain of talin.  These results begin to describe the function of the Myo10‐β‐integrin interaction, but unanswered questions still exist.   Although I have shown that integrins can co‐transport with Myo10 in filopodia, it remains unknown if Myo10 is required for these movements.  Additionally, the details of these movements remain unclear.  Does Myo10 bind to integrins regardless of their ligand status, or can Myo10 only bind unliganded/liganded integrins?  We can glean some insight into this issue from the co‐transport experiments performed here.  I 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routinely observed stable puncta of integrins localized along the shafts of filopodia (as seen in Figure 4.5).  These are likely sites of filopodia shaft adhesions, where integrins are engaged with the ECM, and have been reported by others (Steketee and Tosney, 2002).  Importantly, I almost always observed a corresponding, stable puncta of Myo10 overlapping with the stable integrin adhesion.  This may represent molecules of Myo10 engaging ECM‐bound integrins within a filopodia adhesion to provide traction along the filopodium.   Molecules that are present at the tips of filopodia, such as Myo10 and integrins, are proposed to associate with each other in a filopodial tip complex.   In addition to integrins, Myo10 can also bind VASP – another protein that is found at the tips of filopodia and is important for filopodia formation.  As more protein interactions are identified between tip‐localizing proteins, we must ask, what is the function of the filopodial tip complex?  One possibility is that this complex provides the correct components and environment to facilitate actin polymerization at the tip of the filopodium.  Indeed, the proteins that are known to localize to the filopodial tip (Table 3.1) posses the necessary abilities – anti‐capping, nucleating, elongating, membrane curving, and bundling.  In another scenario, the filopodial tip complex may serve as a type of filopodia‐specific adhesion, similar to a focal adhesion.  It is clear that integrins localize to distinct locations at the tips and along the lengths of filopodia, and Myo10 could provide a link between the filopodial integrins and actin to mediate traction at a filopodial adhesion.   When live‐cell imaging Myo10 with other components of the tip complex, such as integrins and VASP, we see these proteins co‐localize at the tips of filopodia in large 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puncta.  Additionally, we often see a fragment of this large puncta break off and travel rearward back towards the cell body.  These fragments of the filopodial tip complex can move back and forth within a filopodium for the duration of an imaging experiment, sometimes pausing within their run.  What is the function of these mobile tip‐complex fragements?  Perhaps they on their way back to the cell body to be endocytosed and recycled.  Alternatively, they may have they broken off of the tip to become a shaft adhesion?  It will be important to explore these and other questions regarding the composition and function of the filopodial tip complex. Myo10 localizes to the tips of filopodia and is likely to play an important role in the function of the tip complex.  However, the forward and rearward movements of Myo10 in filopodia suggest that it has an additional function in filopodia maintenance.  The ability of Myo10 to undergo intrafilopodial motility, combined with its capability to bind several tip complex proteins, implies that Myo10 can function to carry cargoes to and from the tips of filopodia (diagrammed in Figure 2.6).  As filopodia can reach lengths of tens of microns or greater, intrafilopodial motility provides an ideal mechanism to transport molecules between the cell body and the distal tips of filopodia.  This would be important for actin‐associating proteins in the tip complex as well as receptors and signaling proteins.  Interestingly, Myo10 has been shown to bind to and co‐localized with VASP (Tokuo and Ikebe, 2004), integrins (Zhang et al., 2004), the BMP receptor Alk6 (Pi et al., 2007), and the netrin‐1 receptor (Zhu et al., 2007).  It was previously reported that Myo10 co‐transports with VASP and Alk6 and I show here for the first time that Myo10 co‐transports with β1‐ and β3‐integrins.  It will be important to determine if Myo10 binds to and co‐transports with other filopodial‐tip complex 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proteins such as fascin and mDia2.  Similarly, it will be interesting to find out if Myo10 binds to other receptors that are reported to localize to the tips of filopodia, like EGFR and VEGFR.  Furthermore, if Myo10 does co‐transport with these receptors, what purpose does this co‐transport serve?  While it is possible that Myo10 may carry new and unliganded receptors out to the tips of filopodia, it is also possible that Myo10 may carry ligand bound receptors back to the body of the cell where they can be endocytosed.  Using GFP‐EGFR and quantum dot‐tagged EGF, Lidke et al. reported that ligand bound EGFR traveled rearward in filopodia, back to the body of the cell, where it was endocyosed at the base of the filopodium.  Interestingly, preliminary experiments that I performed using CFP‐Myo10, GFP‐EGFR, and red quantum dot‐tagged EGF revealed that Myo10 can move forward and rearward coordinately with liganded EGFR in A431 cells.  It will be important to further test EGFR and other candidate cargoes for Myo10 binding and co‐transport.  Filopodia are hypothesized to function as organelles of exploration.  They dynamically extend and retract to interact with the cell’s surroundings and receive extracellular cues.  Myo10 plays several important roles in filopodia formation, maintenance, and function and is undoubtedly a critical component in filopodial biology.  Clearly defining the function of Myo10 in the filopodial tip complex and during intrafilopodial motility will surely reveal interesting and important insights.  
MYOSIN­XIX Myo19 was discovered in a study using sequence analysis to predict uncharacterized myosins.  It represented the last unidentified myosin in humans and 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appears to be vertebrate‐specific.  Surprisingly, endogenous and exogenous Myo19 localizes to the mitochondria in several cell types.  This was an exciting result, as no vertebrate myosin is known to associate with mitochondria.  Myo19 appears to associate with mitochondria through its tail domain, which, unexpectedly, has no obvious sequence homology with proteins in the database.  Although it appears that the association is not due to insertion of the Myo19 tail into the mitochondrial membrane, it is unknown if the tail associates with the surface of the mitochondria directly, or if it binds to another protein associated with the mitochondria.  It will be important to determine how Myo19 recognizes and interacts with mitochondria. When we over‐expressed GFP‐Myo19 in several cell types, we observed a striking gain of function phenotype.  GFP‐Myo19 induced a dramatic increase in mitochondrial motility and dynamics.  This movement was independent of the microtubule cytoskeleton, but dependent on the presence of actin.  We were excited to observe this result and sought to determine the Myo19 loss of function phenotype.  I developed and tested an siRNA‐mediated system to knock‐down Myo19, but the effects of this knock‐down remain unknown.  The gain of function phenotype resulted in an increase in mitochondrial movements, so it is likely that knock‐down of Myo19 may reveal a decrease in mitochondrial dynamics.  Alternatively, Myo19 may function to position or anchor mitochondria in certain areas of the cell, which could be particularly critical in polarized cells where local energy needs are disparate across the cell.  Myo19‐mediated positioning of mitochondria could also be required during cell division, where organelles such as mitochondria must be partitioned equally into daughter cells.  Finally, Myo19 may be important for the regulation of microtubule‐mediated 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mitochondrial movements.  Kinesins and dyneins are known to interact with mitochondria and transport them along microtubules (Nangaku et al., 1994; Tanaka et al., 1998; Martin et al., 1999; Waterman‐Storer et al., 1997).  It is possible that Myo19 is responsible for creating pauses during the transport of mitochondria on microtubules by interacting with actin as it passes by.  It will be essential to explore various cellular scenarios when testing for the function of endogenous Myo19.   In addition to uncovering the loss of function phenotype in Myo19 knock‐down cells, it will also be informative to determine how Myo19‐mediated mitochondrial motility is regulated.  In our gain of function experiments, we over‐expressed GFP‐Myo19 in cells that contained endogenous Myo19, however, in the absence of over‐expression, these cells showed low levels of mitochondrial dynamics.  If Myo19 is present in these cells, then what is keeping it “turned off”?  Conversely, what induces Myo19 movements?  As calcium homeostasis is one of several mitochondrial functions, and many myosins are regulated by the calcium‐binding light chain, calmodulin, it is possible that local fluctuations in calcium levels could influence Myo19.  Additionally, movements of mitochondria are important for localizing the cell’s powerhouse to areas in need of ATP.  Myosins are ATPases and require ATP to translocate along actin.  Perhaps Myo19 drives movement of mitochondria until it stops as a result of low local ATP concentration.  This would ensure that mitochondria are trafficked to an area of the cell that is in need of ATP production.   Actin dependent movements of mitochondria in mammalian cells have previously been described (Morris and Hollenbeck, 1995), but until now, no myosin was known to associate with mitochondria in mammalian cells.  The discovery and 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initial characterization of Myo19 provides the first example of a vertebrate‐specific myosin that associates with mitochondria and implicates Myo19 in an actin‐based form of mitochondrial motility.  It will be fascinating to uncover the cell biological functions of this novel mitochondria‐associated myosin. 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